Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 15/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129324 | 0.92 | KDM1A (0.46) | CYP19A1KDM1ACYP11B2CYP11B1 | |
| SCHEMBL12060813 | 0.89 | CYP19A1 (0.37) | CYP19A1CYP17A1 | |
| SCHEMBL3617615 | 0.87 | KDM1A (0.41) | CYP19A1KDM1ACYP11B2CYP11B1 | |
| SCHEMBL1129017 | 0.82 | SIGMAR1 (0.39) | CYP19A1CYP17A1 | |
| SCHEMBL3617961 | 0.81 | CYP11B2 (0.37) | CYP19A1CYP11B2CYP11B1CYP17A1 | |
| SCHEMBL1129028 | 0.80 | SIGMAR1 (0.43) | KDM1ACYP17A1 | |
| SCHEMBL742434 | 0.79 | CYP19A1 (0.42) | CYP19A1KDM1ACYP11B2CYP11B1KCNH2 | |
| SCHEMBL1129577 | 0.79 | MAP3K5 (0.35) | CYP19A1CYP11B2CYP11B1KCNH2 | |
| SCHEMBL3396999 | 0.79 | CYP19A1 (0.37) | CYP19A1KDM1ACYP11B2CYP11B1KCNH2 | |
| SCHEMBL1129448 | 0.79 | CYP11B2 (0.35) | CYP19A1CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071774-B2 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-8071774-B2 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-01-14 | — | — | US | disclosed |
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2010-01-14 | — | — | US | disclosed |
| WO-2006128852-A2 | HETEROCYCLIC SPIRO-COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010015-A1 | Heterocyclic spiro-compounds as aldosterone synthase inhibitors | REN, NR3C2, CYP21A2 | CYP19A1 67/4885KDM1A 3415/4885CYP11B2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.